Europe Hypertrophic and Keloid Scar Treatment Market Developments and Forecast by 2027

The hypertrophic and keloid scar treatment market in Europe is expected to grow from US$ 1,376.88 million in 2020 to US$ 2,705.59 million by 2027; it is estimated to grow at a CAGR of 10.1% from 2020 to 2027.

The UK, Germany, and France are major economies in Europe. Growing cases of injuries is the major factor driving the growth of the Europe hypertrophic and keloid scar treatment market. Injuries and their extension deep into the dermis are the major cause of hypertrophic and keloids scars. Injuries can be further classified as scratches, burns, cuts, gashes, sutures, surgical incisions, and so on. The prevalence rate of injuries ultimately converting to a keloid or hypertrophic scars is 5–15%. In addition, skin conditions such as acne and dark pigmentation also lead to hypertrophic and keloid scar development. The cases of different types of injuries are commonly seen among all age groups. Acne, sports injuries, and road accidents are more common among youngsters. Acne is also a common problem among middle-aged people, irrespective of their gender. The hormonal imbalance among people leads to acne, which might leave severe scars on skin. Acne is estimated to be affecting ~10% of the total global population. According to the WHO data published in February 2020, road accident-led injuries are the leading cause of death among young adults aged 5–29. ~1.35 million fatalities are registered per year due to road accidents. However, the rate of severe injuries by road accidents is also rising. Therefore, the increasing number of accidents is indirectly leading to the rising demand for hypertrophic and keloid scar treatments, which is further anticipated to drive the market in Europe.

Spain, Italy, Germany, France, and the UK are the most affected countries in Europe, owing to the increasing number of COVID-19 cases and deaths. As per the Worldometer, in Spain, Italy, Germany, France, and the UK, the number of cases is 2.25 million, 2.37 million, 2 million, 95 million, 3.36 million, respectively. The number of deaths in these countries is also high. As per the news article, in Italy, due to the COVID-19 emergency, access for thousands of cancer patients in need of chemotherapy, scans, transplants, and surgery has become difficult. There is several issued guidance from national and international organizations trying to help cope with suspected or verified COVID-19 patients. Besides, Germany has prolonged its pandemic prohibitions, including closing schools and shops, until mid-February due to fears that new COVID-19 mutations could cause a further increase in cases. In addition to extending the closing of restaurants, shops, and schools until February 14, Merkel and the governors of Germany's 16 states decided to enable citizens to wear more functional FFP2 or KN95 masks on public transport and supermarkets. Employers would now be ordered to encourage workers to work from home, wherever possible, to prevent office-driven infections. Hypertrophic and keloid scar treatment patients are considered less sensitive from COVID-19 than the general population. Europe has long been within an area of dynamic development in dermatology procedures, adapting to different cultures, traditions, and surgical and medical philosophies. In recent times, these changes have been even more significant and rapid.

Europe Hypertrophic and Keloid Scar Treatment Market Segmentation

Europe Hypertrophic and Keloid Scar Treatment Market – By Scar Type

• Hypertrophic
• Keloid

Europe Hypertrophic and Keloid Scar Treatment Market – By Product Type

• Injectables
• Topical
  • Gels
  • Silicone Sheets
  • Creams
  • Other
• Laser
  • CO2
  • Pulse-Dyed
  • Other
• Other

Europe Hypertrophic and Keloid Scar Treatment Market – By End User

• Hospitals
• Clinics
• Homecare

Europe Hypertrophic and Keloid Scar Treatment Market, by Country

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Europe Hypertrophic and Keloid Scar Treatment Market-Companies Mentioned

• Alliance Pharma PLC
• HRA Pharma
• Mölnlycke Health Care AB.
• Newmedical Technology Inc.
• Perrigo Company plc
• Lumenis
• Smith & Nephew
• Sonoma Pharmaceuticals, Inc
• Suneva Medical

Europe Hypertrophic and Keloid Scar Treatment Report Scope